Prescription drug · NDA
Baqsimi (glucagon) NDC 0548-8351
Glucagon 3 mg/1 · Powder · Nasal · Amphastar Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0548-8351-01 | 00548835101 | 1 TUBE in 1 CARTON (0548-8351-01) / 1 BOTTLE, UNIT-DOSE in 1 TUBE / 1 POWDER in 1 BOTTLE, UNIT-DOSEMarketed from Mar 15, 2024 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Baqsimi
- Generic name (nonproprietary)
- glucagon
- Active ingredients
- Glucagon — 3 mg/1
- Dosage form
- Powder
- Route
- Nasal
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 210134
- Marketing start
- Listing expires
- Other FDA classes
- Decreased GI Motility (Physiologic effect)Decreased GI Smooth Muscle Tone (Physiologic effect)Decreased Glycolysis (Physiologic effect)Increased Gluconeogenesis (Physiologic effect)Increased Glycogenolysis (Physiologic effect)
- Identifiers
- Product ID 0548-8351_8d3aa4dd-737c-49b4-af0d-fe95e3bee54dSPL ID 8d3aa4dd-737c-49b4-af0d-fe95e3bee54dSPL set ID f1f5df9b-872f-44e5-a18f-f0b68e7e9254RxCUI 2180666, 2180671UNII 76LA80IG2G
- Pharmacologic class
- Antihypoglycemic Agent; Gastrointestinal Motility Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400548835101followed by a unit qualifier and the quantityPackage 00548-8351-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
BAQSIMI™ is indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. BAQSIMI ® is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in adults and pediatric patients aged 1 year and older with diabetes. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 210134
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.